Targeted therapies to treat adults with moderate-to-severe plaque psoriasis in the Russian Federation: number needed to treat and cost per responder

Bakulev A.L.; Mladov V.V.; Sokolova V.D.; Tolkacheva D.G.

doi:https://doi.org/10.17116/medtech20204204158

Bakulev A.L.

Razumovsky Saratov State Medical University

Mladov V.V.

Russian Academy of National Economy and Public Administration Under the President of the Russian Federation

Sokolova V.D.

Russian Academy of National Economy and Public Administration Under the President of the Russian Federation

Tolkacheva D.G.

Russian Academy of National Economy and Public Administration Under the President of the Russian Federation

Targeted therapies to treat adults with moderate-to-severe plaque psoriasis in the Russian Federation: number needed to treat and cost per responder

Authors:

Bakulev A.L., Mladov V.V., Sokolova V.D., Tolkacheva D.G.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2020;42(4): 58‑74

DOI: 10.17116/medtech20204204158

Read: 1256 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Bakulev AL, Mladov VV, Sokolova VD, Tolkacheva DG. Targeted therapies to treat adults with moderate-to-severe plaque psoriasis in the Russian Federation: number needed to treat and cost per responder. Medical Technologies. Assessment and Choice. 2020;42(4):58‑74. (In Russ.)
https://doi.org/10.17116/medtech20204204158

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To determine the number of adults with moderate-to-severe plaque psoriasis needed to treat (NNT) for achievement of one PASI 75/90 response and cost per responder (CpR) after 12 weeks and one year of therapy for each drug analyzed.

MATERIAL AND METHODS

The study is based on previously published results of a systematic review and meta-analysis comparing the effectiveness of targeted drugs (netakimab, ixekizumab, secukinumab, adalimumab, infliximab, etanercept, ustekinumab, certolizumab pegol, guselkumab, apremilast and tofacitinib) in adult patients with moderate-to-severe plaque psoriasis in the Russian Federation. The surface under the cumulative ranking curve (SUCRA) analysis was used to summarize results for each outcome. The risk differences (RD) between targeted therapies and placebo, corresponding NNT and CpR values were calculated for PASI 75/90.

RESULTS

For PASI 75, the lowest NNT values were obtained for IL-17 inhibitors: netakimab, ixekizumab, and secukinumab, IL-23 inhibitor guselkumab, as well as tumor necrosis factor alpha (TNF-α) inhibitor infliximab. Higher values were demonstrated by anti-TNF-α certolizumab pegol and adalimumab, as well as IL-12/23 inhibitor ustekinumab. It requires to treat less than 2 patients with either netakimab, ixekizumab, or guselkumab to achieve one PASI 90 response. At least 1 out of 3 patients will achieve PASI 90 following secukinumab, infliximab, or adalimumab treatment, while certolizumab pegol and ustekinumab may require more patients to be treated. Etanercept and apremilast showed the highest NNT for PASI 75/90. Netakimab demonstrated the lowest costs per PASI 75/90 responder after 12 weeks and 1 year of treatment. Etanercept and small molecules: apremilast and tofacitinib, showed the highest CpR between all targeted drugs. These drugs are the least cost-effective treatment options.

CONCLUSION

This study complements the systematic review and meta-analysis of relative effectiveness of targeted drugs in adults with moderate-to-severe plaque psoriasis in Russia. The results may become a useful tool for treatment decision-making.

Keywords:

plaque psoriasis

systematic review

network meta-analysis

biologics

targeted drugs

Authors:

Bakulev A.L.

Razumovsky Saratov State Medical University

Mladov V.V.

Russian Academy of National Economy and Public Administration Under the President of the Russian Federation

Sokolova V.D.

Russian Academy of National Economy and Public Administration Under the President of the Russian Federation

Tolkacheva D.G.

Russian Academy of National Economy and Public Administration Under the President of the Russian Federation

Received:

06.10.2020

Accepted:

22.10.2020

Close metadata

References:

Gaziev AR, Oslopov VE, Shamov BA, et al. Psoriasis and hemostasis. Prakticheskaya meditsina. 2013;73(1-4):20-23. (In Russ.).
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271. https://doi.org/10.1016/S0140-6736(07)61128-3
Sokolovsky EV, Kruglova LS, Ponich ES. «The flaws» of total systems therapy with biological preparations in psoriasis. Rossiyskij zhurnal kozhnykh i venericheskikh boleznej. 2015;18(6):32-38. (In Russ.).
Bakulev AL, Shagova YuV, Kozlova IV. Psoriasis as system pathology. Saratovskij nauchno-meditsinskij zhurnal. 2008;4(1):13-20. (In Russ.).
Bolotnaya LA. Psoriasis: pathogenesis, clinical manifestations, principles of therapy. Vostochnoevropejskij zhurnal vnutrennej i semejnoj meditsiny. 2015;(1):4-9. (In Russ.). https://doi.org/10.15407/internalmed2015.01.004
Tablazon IL, Al-Dabagh A, Feldman SR. Risk of cardiovascular disorders in psoriasis patients. Am J Clin Derm. 2013;14(1):1-7. https://doi.org/10.1007/s40257-012-0005-5
Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233-239.
Kovtunova VA, Dumchenko VV, Bakhmutova EG. Experience of the long-term use of anticytokine therapy in psoriasis. Rossijskij zhurnal kozhnykh i venericheskikh boleznej. 2017;20(3):163-166. (In Russ.). https://doi.org/10.18821/1560-9588-2018-21-2-85-89
Mishina OS. Organizatsiya meditsinskoj pomoshchi khronicheskim bol’nym na protyazhenii vsej zhizni. Metodicheskie rekomendatsii. M.: RIO TsNIIOIZ MZ RF; 2016. (In Russ.).
Metodicheskie rekomendatsii po otsenke sravnitel’noj klinicheskoj effektivnosti i bezopasnosti lekarstvennogo preparata. 2016. (In Russ.). Accessed October 30, 2020. https://rosmedex.ru/wp-content/uploads/2016/12/MR-E%60B-23.12.2016.pdf
Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision Making. 2011. Accessed October 30, 2020. https://nicedsu.org.uk/wp-content/uploads/2016/03/TSD1-Introduction.final_.08.05.12.pdf
Tolkacheva DG, Sokolova VD, Mladov VV. Effectiveness and safety of targeted drugs for the treatment of adults with moderate-to-severe plaque psoriasis in the Russian Federation. Medical Technologies. Assessment and Choice. 2019;4:76-86. (In Russ.). https://doi.org/10.31556/2219-0678.2019.38.4.076-086
Armstrong AW, Betts KA, Signorovitch JE, et al. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. Curr Med Res Opin. 2018;34(7):1325-1333. https://doi.org/10.1080/03007995.2018.1457516
Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalized Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomized Controlled Trials. 2016.
Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU Technical Support Document 3: Heterogeneity. Subgroups, Meta-regression, Bias and Bias-Adjustment. 2012.
Mbuagbaw L, Rochwerg B, Jaeschke R, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017;6(1):1-5. https://doi.org/10.1186/s13643-017-0473-z
Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29:645-648. https://doi.org/10.1111/jdv.12817
Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728-1733. https://doi.org/10.1056/NEJM198806303182605
McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712-720. https://doi.org/10.7326/0003-4819-126-9-199705010-00007
Bender R, Kuss O, Hildebrandt M, Gehrmann U. Estimating adjusted NNT measures in logistic regression analysis. Stat Med. 2007;26(30):5586-5595. https://doi.org/10.1002/sim.3061
Straus SE, Glasziou P, Richardson WS, Haynes RB. Evidence-based medicine: how to practice and teach it. London: Churchill Livingstone. 2011.
Mt-Isa S, Hallgreen CE, Wang N, et al.; IMI-PROTECT benefit-risk participants. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf. 2014;23(7):667-678. https://doi.org/10.1002/pds.3636
Mendes D, Alves C, Batel MF. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. Expert Opin Drug Saf. 2016;15(10): 1301-1312. https://doi.org/10.1080/14740338.2016.1217989
Higgins J, Thomas J. Cochrane Handbook for Systematic Reviews of Interventions, v.6.1, section 15.4. Interpreting results from dichotomous outcomes (including numbers needed to treat), 2020. Accessed October 30, 2020. https://training.cochrane.org/handbook/current/chapter-15#section-15-4
Protokol zasedaniya komissii Ministerstva zdravookhraneniya Rossijskoj Federatsii po formirovaniyu perechnej lekarstvennykh preparatov dlya meditsinskogo primeneniya i minimal’nogo assortimenta lekarstvennykh preparatov, neobkhodimykh dlya okazaniya meditsinskoj pomoshchi. Ot 4 avgusta 2020 g. Accessed October 30, 2020. (In Russ.). https://minzdrav.gov.ru/ministry/61/10/stranitsa-858/protokol-zasedaniya-komissii-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-po-formirovaniyu-perechney-lekarstvennyh-preparatov-dlya-meditsinskogo-primeneniya-i-minimalnogo-assortimenta-lekarstvennyh-preparatov-neobhodimyh-dlya-okazaniya-meditsinskoy-pomoschi-ot-4-avgusta-2020-goda
Protokol zasedaniya komissii Ministerstva zdravookhraneniya Rossijskoj Federatsii po formirovaniyu perechnej lekarstvennykh preparatov dlya meditsinskogo primeneniya i minimal’nogo assortimenta lekarstvennykh preparatov, neobkhodimykh dlya okazaniya meditsinskoj pomoshchi. Ot 6 fevralya 2020 g. Accessed October 30, 2020. (In Russ.). https://minzdrav.gov.ru/ministry/61/10/stranitsa-858/protokol-zasedaniya-komissii-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-po-formirovaniyu-perechney-lekarstvennyh-preparatov-dlya-meditsinskogo-primeneniya-i-minimalnogo-assortimenta-lekarstvennyh-preparatov-neobhodimyh-dlya-okazaniya-meditsinskoy-pomoschi-60220
Wu AG, Conway J, Barazini L, et al. Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in Psoriasis Clearance. Dermatol Ther. 2020;10(5):1155-1163. https://doi.org/10.1007/s13555-020-00435-2
Merola JF, Amato DA, See K, et al. Evaluation of sPGA×BSA as an Outcome Measure and Treatment Target for Clinical Practice. J Invest Dermatol. 2018;138(9):1955-1961. https://doi.org/10.1016/j.jid.2018.01.041
Walsh JA, Jones H, Mallbris L, et al. The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis: Targets and Therapy. 2018;8:65-74. https://doi.org/10.2147/PTT.S169333
Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. Committee for Medicinal Products for Human Use (CHMP). 2005. Accessed October 30, 2020. https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-indicated-treatment-psoriasis
Ravasio R, Antonelli S, Maiorino A, et al. Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Glob Reg Health Technol Ass. 2019;1-9. https://doi.org/10.1177/2284240318822289
Imafuku S, Nakano A, Dakeshita H, et al. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan. J Dermatolog Treat. 2018; 29(1):24-31. https://doi.org/10.1080/09546634.2017.1341607
Frolov MYu, Rogov VA, Salasyuk AS. Pharmacoeconomic analysis of using genetically engineered biologic drugs for treating adult patients with moderate to severe plaque psoriasis in the Russian Federation. Farmatsevticheskoe delo i tekhnologiya lekarstv. 2020; 1:56-65. (In Russ.). https://doi.org/10.33920/med-13-2001-06
Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58(7):1981-1991. https://doi.org/10.1002/art.23606
Bakulev AL Samtsov AV, Kubanov AA, et al. Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext. Vestnik dermatologii i venerologii. 2019;95(3):54-64. (In Russ.). https://doi.org/10.25208/0042-4609-2019-95-3-54-64
Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507-1514. https://doi.org/10.1111/jdv.14878